JNJ Quantitative Stock Analysis

Johnson & Johnson (JNJ) received a 77% rating from Validea's P/B Growth Investor model, based on Partha Mohanram's strategy for identifying low book-to-market stocks with sustained growth potential. This score, while strong, falls just below the 80% threshold indicating 'some interest' for the model, suggesting JNJ aligns well with many of the strategy's fundamental criteria but not all for a high conviction signal.

Analysis

Johnson & Johnson (JNJ) registers a moderately positive fundamental profile according to Validea's P/B Growth Investor model, scoring 77%. While solid, this rating falls just shy of the 80% threshold that indicates active interest from this specific quantitative strategy, which seeks low book-to-market stocks with markers of sustained growth. JNJ successfully passes key tests for its Book/Market Ratio, Return on Assets (ROA), and Cash Flow from Operations to Assets, signaling a reasonable valuation and operational efficiency. The model also favorably views the low variance in both ROA and sales, suggesting business stability. However, the analysis flags two notable weaknesses: JNJ fails on the comparison of cash flow from operations to its ROA, which can sometimes indicate lower earnings quality, and it also fails the screen for Research and Development to Assets. This latter point is particularly salient for a large-cap firm in the Biotechnology & Drugs industry, as it may suggest that R&D investment, a key driver of future growth, is not keeping pace with the company's asset base according to the model's criteria.

Key Decisions for Investors

• Given the 77% score is below the model's 80% interest threshold, this report serves as a neutral-to-positive data point rather than a high-conviction buy signal, warranting further due diligence before initiating or adding to a position.
• Investors should closely examine the two failing criteria, specifically investigating the quality of earnings by comparing cash flow to net income and assessing whether the company's R&D expenditure is sufficient to support a long-term competitive advantage in the pharmaceutical sector.
• Consider that JNJ's profile aligns with a stable, large-cap company but may not satisfy investors seeking aggressive growth, as indicated by the model's specific concerns around R&D investment levels relative to assets.